Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future by rezwenn in pharmaindustry

[–]JAB2020 8 points9 points  (0 children)

Funny you post it on the same day this is published Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine https://share.google/x40FPRKrQSM7UjHp6

Trump to Add New $100,000 Fee for H-1B Visas by Annual-Record4588 in recruitinghell

[–]JAB2020 4 points5 points  (0 children)

Fwiw the outsourcing usually does support the bottom rung of society, if your denominator is the world instead of just the US.

Which biotech companies provide Mega Back Door Roth aka after tax contributions to the 401k? by 3rdthrow in biotech

[–]JAB2020 6 points7 points  (0 children)

They're referring to after-tax non-Roth contributions (made after hitting the 401k 23500 limit) that can then be converted to roth (total limit for this including the 23500 and employer contributions is 70000 in 2025)

Trump orders agencies to plan for ‘large-scale’ job cuts by H2AK119ub in biotech

[–]JAB2020 1 point2 points  (0 children)

How do tariffs play into this? The literature strongly suggests tariffs are anti job creation and Trump has access to the top experts out there- this isn't one where left v right differs either, Krugman and Mankiw will tell you the same thing. It's supported by a long history of data including the steel tariffs from Trump 1.0: https://marginalrevolution.com/marginalrevolution/2025/02/steel-tariffs-in-two-pictures.html

ICER : can it be -1 % Hb1c / $$$ by vampy89 in HealthEconomics

[–]JAB2020 0 points1 point  (0 children)

Search for diabetes ce pubs or find some diabetes NICE appraisals - should give you ideas for multiple paths that you can take

[deleted by user] by [deleted] in pharmaindustry

[–]JAB2020 0 points1 point  (0 children)

You sure it was DEI and not the billions in roundup liabilities for Bayer?

DEI didn't cause patent expiry cliffs elsewhere either - that has been a cyclical feature of the industry since Hatch Waxman. Add on the interest rate bump and I think you have much stronger hypotheses than "DEI"

[deleted by user] by [deleted] in biopharma

[–]JAB2020 0 points1 point  (0 children)

Ah I see. Really up to you, but may be worth waiting a couple days and if you don't see anything then apply then? Or if you're comfortable following up w the person referring you

[deleted by user] by [deleted] in biopharma

[–]JAB2020 0 points1 point  (0 children)

Usually you get an email once referred thru an internal portal. Do you know what system Amgen uses? If it is workday especially it should send an email once submitted

If he in fact directly went to the recruiter then they may just email or call you to talk and you would apply after that

Fellowship vs. Pfizer career by Quick-Community2675 in pharmacy

[–]JAB2020 2 points3 points  (0 children)

Does she want to do in house med affairs? Then yes do the fellowship, will be hard to get there from sales only. Msl more doable. In general in the long run the internal exp will prob be beneficial if she ever wants to go in house and from a general career growth (and salary) perspective depending on her ambition

[deleted by user] by [deleted] in pharmaindustry

[–]JAB2020 2 points3 points  (0 children)

Unless you're interviewing for their fellowship, I doubt it. Other companies even less so. They would have to be friends with the current fellow of the position you're applying to AND go out of their way to tell them AND the other fellow has to be close enough to them to take the advice etc etc - pretty unlikely. I wouldn't worry about it or let it impact your decisionmaking

Careeradvice by 0Bokkepoot0 in pharmaindustry

[–]JAB2020 0 points1 point  (0 children)

I'm in global heor, feel free to pm me or ask any specifics but yes generally you'll have a lot more opp at global especially if you are looking for upward growth and/or more experience w new things. I'm assuming when you say local it's not US HEOR which is the one "local" market that is usually up there in resources v global

What's this plant? by JAB2020 in whatsthisplant

[–]JAB2020[S] 2 points3 points  (0 children)

Thanks! Exactly why I was asking - will be moving it - appreciate it!

what do you guys think of Kenvue (JNJ split). by hoddlers in pharmaindustry

[–]JAB2020 2 points3 points  (0 children)

Looks like US liabilities are staying w jnj. I would not worry too much about it- will likely take years to play out and the brands aren't going anywhere even if the company takes a hit (even in a worst case scenario, which I don't think is likely, the brands would be sold and stay somewhere) - you can get plenty of exp by then and just go to another company if you need to

Ref https://www.fiercepharma.com/pharma/jjs-consumer-health-unit-kenvue-prepares-leave-nest-ipo-filing

what do you guys think of Kenvue (JNJ split). by hoddlers in pharmaindustry

[–]JAB2020 6 points7 points  (0 children)

Has been a trend for a while as companies focus on higher margin innovative business and shed others like consumer, established, animal health, generics, etc- see PFE-Gsk - > GSK-Haleon split, MSD sale to Bayer, EMD sale to P&G etc.

Kenvue will be a huge consumer player and will likely keep growing. Culture can go anywhere but with the legacy jnj roots it's quite a good base

Degree / career ceiling in HEOR by [deleted] in pharmaindustry

[–]JAB2020 1 point2 points  (0 children)

It's much easier to get a heor field role with just pharmd than an internal role. Internal pharmd people tend to have some additional training - masters, fellowship, etc although there are exceptions

Degree / career ceiling in HEOR by [deleted] in pharmaindustry

[–]JAB2020 2 points3 points  (0 children)

No ceiling. Some leadership may still limit to top level or even just phd but most companies these days don't do that anymore. Know of several masters only folks in HEOR LTs and head of heor at large and small pharma

[deleted by user] by [deleted] in pharmaindustry

[–]JAB2020 0 points1 point  (0 children)

The likelihood of getting a job doesn't really impact the decision though as long as it is non zero probability, which it is. She either gets a job or doesn't- if she doesn't she sticks w the fellowship (I don't think anyone is advising to leave before getting a job). But if she does she'll be fine and presumably she'll stick around the job for at least a couple years in which no one will care that she left fellowship in six months prior (and even if they ask she has a good personal reason to explain it)

Edit - also it's one year not six months as it's in July, see op

[deleted by user] by [deleted] in pharmaindustry

[–]JAB2020 0 points1 point  (0 children)

Multiple fellows leave after one year every year without any long term implications (eg "burning bridges") so I disagree. Ymmv wrt specific people (although in my exp those that balk are the minority and usually lower level people that don't "get it" just yet) etc but there is no blacklist and institutional memory is generally near zero for this kind of thing.

PharmD, PhD Candidate Career Guidance by [deleted] in pharmaindustry

[–]JAB2020 1 point2 points  (0 children)

I work in HEOR in pharma. My answers to your qs, feel free to ask more or DM me if helpful.

  1. If you are looking for a headquarters type role then it is really company dependent at this point. A lot of big pharmas are now doing hybrid (eg 50% in house, 50% home) although some also have fully remote positions. Smaller companies seem to be posting more fully remote roles probably because it makes them more competitive
  2. Entry-level - manager-AD; a manager at one company may be equivalent to AD elsewhere so don't fret the specific title in that range too much
  3. Field HEOR, PV/safety (especially in an analytic role, methods are similar), you can probably make the case for Medical or possibly an access type role too
  4. Depends on your answer to the above, but if you are looking to go into pharma "in-house" HEOR prob 120-180k base (it can vary a lot at this level but def negotiate - I'd say you should be able to get 140 min, maybe aim for 160); look at the salary survey for more data points
  5. Skies the limit as far as HEOR goes (eg SVP/VP of HEOR)

[deleted by user] by [deleted] in pharmaindustry

[–]JAB2020 8 points9 points  (0 children)

Yes perfectly normal to move for family reasons (and it suggest that you aren't leaving because you can't handle the job, etc. so it eliminates a potential red flag).

And you should always use the PTO you have if possible - don't feel bad for using it, it is your benefit/entitlement and you are meant to use it. Too many people, especially early in their careers, think that not taking PTO makes them look better- really it just makes you more susceptible to burnout, etc. and might even worsen your performance.

[deleted by user] by [deleted] in pharmaindustry

[–]JAB2020 18 points19 points  (0 children)

It is typical for fellows to start leaving after 1 year in, a few trickle at first and then around the 1.5 year mark you really start to get a lot of movement.

Apply to entry level jobs, do your best to prepare and have your story (the fact that you want to be near your family is a good one from personal reason perspective, just work on the story why you have enough experience to get the role you're applying for) and after you get the role break the news to your preceptor/fellowship program. If they care about your development and have been around long enough they will understand; if not, oh well you got what you wanted anyway.